The 2017 American Society of Gene & Cell Therapy took place in Washington DC last week. The Duchenne community was treated to a wealth of data from projects utilizing gene […]
PTC is committed to getting patients onto EMFLAZA as quickly as possible, without interruption of therapy. For patients that are currently accessing EMFLAZA through Master Pharmacy importation from outside of […]
Twenty years ago I was honored with the greatest gift I could have ever imagined, motherhood. As I think about the most precious gift in my life, my son Hawken, […]
Today, Dr. Eric Olson, PhD, Chair of Molecular Biology at UT Southwestern, was honored to give a presentation at the American Society of Gene & Cell Therapy (ASGCT) 2017 meeting […]
At CureDuchenne we understand that when families are affected by a disease with no cure such as Duchenne muscular dystrophy, finding a sense of community is important. We are pleased […]
Today, PTC Therapeutics hosted a call for the Duchenne community to announce pricing and services for their launch of EMFLAZA, the commercial name for deflazacort. The announced price will be […]
Mother’s Day is a reminder to love our moms a little extra and be thankful for all that they do for us. For boys with Duchenne, it’s a reminder of […]
May 8, 2017 Dear Duchenne Families, Today we shared our plans for the launch of EMFLAZA™ (deflazacort), the first FDA-approved corticosteroid for Duchenne muscular dystrophy patients age 5 and […]
CureDuchenne is pleased to see the positive preliminary data from Capricor Therapeutics on their HOPE clinical trial in Duchenne muscular dystrophy. CureDuchenne Ventures helped fund this clinical trial to address […]
